FAGR Fagron SA

Record revenue of €209 million in first quarter reflecting 15% topline growth

Record revenue of €209 million in first quarter reflecting 15% topline growth

Regulated information - inside information

Nazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET

Record revenue of €209 million in first quarter reflecting 15% topline growth

Fagron, the leading global player in pharmaceutical compounding today publishes its quarterly results for the period ending 31 March 2024.

Key Highlights

  • Revenue growth accelerated to 15.3% reported growth (14.9% at CER) resulting in €209.2 million, supported by all regions
  • Organic growth at CER of 12.3% reflects the continued strong performance in North America and robustness in EMEA
  • Global operational excellence initiatives on track and yielding efficiencies
  • Integration of LSP and Parma Produkt progressing as planned; remain committed to disciplined acquisition strategy
  • FY 2024 outlook of high single-digit organic sales growth and improvement in profitability reaffirmed



Rafael Padilla, CEO of Fagron:         

“I am pleased to report another excellent quarter for Fagron with our teams delivering commendable results. The market dynamics across our regions are challenging, yet Fagron’s business model proves resilient, affirming our unique global positioning and leadership.

Our organic growth is driven by our focused commercial strategy, operational efficiencies, and the successful implementation of our global excellence initiatives. North America in particular has seen record growth with strong underlying demand at both FSS and Anazao. In EMEA, we have delivered a strong performance despite the impact of the change in reimbursement policy in Poland, as other markets compensated adequately, further highlighting the strength of our diversification strategy. In Latin America, growth has slowed slightly this quarter due to seasonal effects, while the competitive and consumer dynamics remained unchanged.

We are on track with the integration of our recent acquisitions and remain committed to exploring market opportunities globally to further strengthen our position.

Overall, we are confident in our outlook and reiterate our FY 2024 and mid-term guidance, as we continue to capitalize on growth opportunities that support our strategic objectives.”

Please open the link below for the full press release:

Attachment



EN
11/04/2024

Underlying

FAGRFagron SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fagron SA

 PRESS RELEASE
Free
FAGR FAGRON SA

Disclosure of a transparency notification from AOC Pharma S.à r.l.

Disclosure of a transparency notification from AOC Pharma S.à r.l. Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 27 02 2026 – 6PM CET Disclosure of a transparency notification from AOC Pharma S.à r.l. Pursuant to the Belgian Act of 2 May 2007 on the disclosure of major shareholdings in listed companies, Fagron received a transparency notification from AOC Pharma S.à r.l., dated 24 February 2026. Notification from AOC Pharma S.à r.l. On 24 February 2026, Fagron received a transparency notification from AOC Pharma S.à r.l., informing the Company that its sharehold...

February 27, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l.

Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Gereglementeerde informatie Nazareth (België)/Rotterdam (Nederland), 27 februari 2026 – 18:00 CET Openbaarmaking van transparantiekennisgeving van AOC Pharma S.à r.l. Overeenkomstig de Belgische Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in beursgenoteerde vennootschappen, ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l., gedateerd 24 februari 2026. Kennisgeving van AOC Pharma S.à r.l. Op 24 februari 2026 ontving Fagron een transparantiekennisgeving van AOC Pharma S.à r.l....

February 27, 2026 1 EN
ING Helpdesk
  • ING Helpdesk
PROX Proximus SA de ...
FAGR FAGRON SA ... (+7)

Benelux Morning Notes

Ackermans & van Haaren: Results capping already strong subsidiary reporting. DPS beat. Fagron: Acquisition of Pharmavit Europe, active in nutraceutical raw materials. Fugro: Patience please. Kendrion: Sees signs of improvement in EU economy. Proximus: 2026 dividend halved, 2028-30 targets a bit better on lower capex. Proximus: 4Q25 in line EBITDA on weaker sales, FCF up; 2026 guidance below on EBITDA. Recticel: Strong FY25 results, CEO transition seen as a negative

PROX PROXIMUS SA DE DROIT PUBLIC
FAGR FAGRON SA
REC RECTICEL SA
ACKB ACKERMANS & VAN HAAREN NV
KENDR KENDRION NV
OBEL ORANGE BELGIUM SA
FUR FUGRO NV
02/27/26 February 27, 2026 1 EN
Guy Sips ... (+7)
  • Guy Sips
  • Hilde Van Boxstael
  • Livio Luyten
  • Mathijs Geerts Danau
  • Michiel Declercq
  • Wim Hoste
  • Wim Lewi
PROX Proximus SA de ...
MTLS MATERIALISE ADS ... (+8)

Morning Notes : ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, R...

: ACKB BB, FAGR BB, FUR NA, MTLS US, MDXH BB, PROX BB, RECT BB, WHATS BB

PROX PROXIMUS SA DE DROIT PUBLIC
MTLS MATERIALISE ADS
FAGR FAGRON SA
TERB TER BEKE N.V.
REC RECTICEL SA
ACKB ACKERMANS & VAN HAAREN NV
FUR FUGRO NV
MDXH MDXHEALTH
02/27/26 February 27, 2026 1 EN
 PRESS RELEASE
Free
FAGR FAGRON SA

Fagron completes strategic acquisition of Pharmavit Europe, strengthen...

Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Regulated information – inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 26 February 2026 – 6:30PM Fagron completes strategic acquisition of Pharmavit Europe, strengthening its leadership in high‑growth nutraceutical ingredients across EMEA Fagron, the leading global player in pharmaceutical compounding, announces that it has completed the acquisition of Pharmavit Europe, a leading European distributor of nutraceutical raw material...

February 26, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch